- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 3.5 Amended and Restated Certificate of Incorporation of Oruka Therapeutics, Inc
- 3.6 Bylaws of Oruka Therapeutics, Inc, As Currently In Effect
- 4.3 Investor Rights Agreement, Dated March 6, 2024, by and Among Oruka Therapeutics, Inc. and Certain Parties Thereto
- 10.40 Oruka Therapeutics, Inc. 2024 Equity Incentive Plan
- 10.41 Form of Restricted Stock Notice and Restricted Stock Purchase Agreement of Oruka Therapeutics, Inc
- 10.42 Form of Stock Option Agreement Under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan
- 10.43 Amended and Restated Director Offer Letter, Dated March 22, 2024, Between Oruka Therapeutics, Inc. and Samarth Kulkarni
- 10.44 Director Offer Letter, Dated April 24, 2024, Between Oruka Therapeutics, Inc. and Kristine Ball
- 10.45 Form of Indemnification Agreement Between Oruka Therapeutics, Inc. and Its Directors and Officers
- 10.46 Amended and Restated Employment Offer Letter, Dated February 14, 2024, by and Between Oruka Therapeutics, Inc. and Lawrence Klein
- 10.47 Amended and Restated Employment Offer Letter, Dated March 11, 2024, by and Between Oruka Therapeutics, Inc. and Arjun Agarwal
- 10.48 Amended and Restated Employment Offer Letter, Dated March 15, 2024, by and Between Oruka Therapeutics, Inc. and Joana Goncalves
- 10.49 Amended and Restated Employment Offer Letter, Dated April 12, 2024, by and Between Oruka Therapeutics, Inc. and Paul Quinlan
- 21.1 List of Subsidiaries of Arca Biopharma, Inc
- 23.1 Consent of KPMG LLP, Independent Registered Public Accounting Firm of Arca Biopharma, Inc
- 23.2 Consent of Pricewaterhousecoopers LLP, Independent Registered Public Accounting Firm of Oruka Therapeutics, Inc
- 99.5 Consent of Lucid Capital Markets, LLC
- 99.6 Consent of Lawrence Klein to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.7 Consent of Kristine Ball to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.8 Consent of Carl Dambkowski to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.9 Consent of Peter Harwin to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.10 Consent of Samarth Kulkarni to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.11 Consent of Cameron Turtle to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- EX-FILING FEES Filing Fee Table
- Download Excel data file
- View Excel data file
- 1 Aug 24 424B3 Prospectus supplement
- 25 Jul 24 EFFECT Notice of effectiveness
- 22 Jul 24 S-4/A Registration of securities issued in business combination transactions (amended)
- 9 Jul 24 S-4/A Registration of securities issued in business combination transactions (amended)
- 18 Jun 24 S-4/A Registration of securities issued in business combination transactions (amended)
-
13 May 24 S-4 Registration of securities issued in business combination transactions
- 22 Jul 24 Registration of securities issued in business combination transactions (amended)
- 9 Jul 24 Registration of securities issued in business combination transactions (amended)
- 18 Jun 24 Registration of securities issued in business combination transactions (amended)
- 13 May 24 Registration of securities issued in business combination transactions
- 24 Nov 08 Registration of securities issued in business combination transactions (amended)
- 30 Oct 08 Registration of securities issued in business combination transactions
- 13 Dec 02 Registration of securities issued in business combination transactions (amended)
Exhibit 99.5
Consent of Lucid Capital Markets, LLC
May 13, 2024
Board of Directors
ARCA biopharma, Inc.
10170 Church Ranch Way, Suite 100
Westminster, CO 80021
Re: Registration Statement on Form S-4 of ARCA biopharma, Inc.
Members of the Board:
We hereby consent to the inclusion of our opinion letter, dated April 2, 2024, to the Board of Directors of ARCA biopharma, Inc. (“ARCA”) as Annex B to, and to the reference thereto under the headings “Prospectus Summary — Opinion of Lucid Capital Markets to the ARCA Board,” “The Merger — Background of the Merger,” “The Merger — ARCA’s Reasons for the Merger,” and “The Merger — Opinion of Lucid, ARCA’s Financial Advisor, to ARCA’s Board of Directors” in the proxy statement/prospectus relating to the proposed merger involving ARCA and Oruka Therapeutics, Inc. (“Oruka”), which such proxy statement/prospectus forms a part of ARCA’s and Oruka’s Registration Statement on Form S-4 (the “Registration Statement”) to be filed on the date hereof, which this consent is filed as an exhibit thereto. In giving the foregoing consent, we do not admit (1) that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended (the “Securities Act”), or the rules and regulations of the Securities and Exchange Commission (the “Commission”) promulgated thereunder, or (2) that we are experts with respect to any part of the Registration Statement within the meaning of the term “experts” as used in the Securities Act and the rules and regulations of the Commission promulgated thereunder.
Very truly yours,
| |
/s/ Lucid Capital Markets, LLC | |
LUCID CAPITAL MARKETS, LLC |
LUCID CAPITAL MARKETS, LLC
570 Lexington Ave, 40th Floor
New York NY 10022